STOCK TITAN

Elite Health Systems’ nine-month net loss hits $4.31M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Elite Health Systems Inc. (EHSI) reported third-quarter revenue of $1.276 million and nine-month revenue of $3.983 million, primarily from its Medicare Advantage and services businesses. Nine-month net loss was $4.312 million, versus $2.026 million a year earlier; operating cash use was $4.035 million. Cash and working capital were $740,000 and $136,000, respectively, at September 30, 2026.

Substantial doubt about continuing as a going concern was raised by losses, liquidity and limited capital access; management believes its plans alleviate that doubt. The board authorized review of financing, asset sales, a merger or other strategic transactions, with no timetable. Disclosure controls were ineffective because of a material weakness in vendor-change verification and approval. The company recorded a $233,000 security-incident loss; the insurer's coverage decision was pending and no recovery was recorded. It also disclosed $1.2 million in subordinated notes with CEO and Chair Dr. Prasad Jeereddi, at 10% annual interest, and warrants for up to 252,631 shares at $0.95.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 5 points

How the balance works

Positive

  • None.

Negative

  • Major pointSubstantial doubt about going concern was raised at September 30, 2026.
  • Major pointDisclosure controls were ineffective at September 30, 2026, due to a material weakness.
  • Moderate pointNine-month net loss reached $4.312 million, versus $2.026 million in 2025.
  • Moderate pointOperating cash use was $4.035 million, versus $1.448 million in 2025.
  • Minor pointThird-quarter net loss was $1.486 million, versus $1.161 million in 2025.

Filing Explained

The agreement leaves up to one million five hundred thousand dollars in further investment as capacity, not funds reported received.

During the quarter ended September 30, 2026, Elite Health Systems issued 161,369 common shares, bringing shares outstanding to 28,682,989; issuing shares increases the total count and reduces existing holders’ percentage ownership, absent offsetting changes.

The notes agreement also allows the company to accept additional investment on the same terms up to $1.5 million; this is capacity, not a disclosure that the additional investment was received.

Third-quarter revenue $1.276 million Three months ended September 30, 2026.
Third-quarter net loss $1.486 million Three months ended September 30, 2026; compared with $1.161 million in 2025.
Nine-month net loss $4.312 million Nine months ended September 30, 2026; compared with $2.026 million in 2025.
Operating cash used $4.035 million Nine months ended September 30, 2026; compared with $1.448 million in 2025.
Cash and cash equivalents $740,000 At September 30, 2026; compared with $3.758 million at December 31, 2025.
Working capital $136,000 At September 30, 2026; compared with $3.144 million at December 31, 2025.
Security-incident loss $233,000 Recognized in other expenses for the period ended September 30, 2026.
Subordinated notes $1.2 million Notes with CEO and Chair Dr. Prasad Jeereddi; funded in July, August and October 2026.
going concern financial
"substantial doubt regarding the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
material weakness technical
"management identified a material weakness as of September 30, 2026"
A material weakness is a significant flaw in the systems and checks a company uses to ensure its financial reports are accurate, meaning errors or fraud could happen and not be caught. For investors it matters because it raises the risk that reported results are unreliable—similar to finding a hole in a ship’s hull—potentially leading to corrected financials, regulatory action, reduced trust, and negative effects on stock value and borrowing costs.
business email compromise technical
"experienced a business email compromise (BEC) security incident"
An attack where scammers trick employees, customers, or partners into sending money or sensitive information by impersonating trusted contacts, like someone forging a check or pretending to be a boss in an email. It matters to investors because successful fraud can cause direct financial losses, damage a company’s reputation and internal controls, lead to regulatory fines, and raise questions about management’s risk oversight — all of which can hurt share value.
Knox-Keene license regulatory
"obtained the Knox-Keene license in California"
variable interest entity financial
"CBOP is considered to be a variable interest entity of the Company"
A variable interest entity (VIE) is a company structure where one party controls another company’s operations and economic outcomes through contracts or special arrangements instead of owning a majority of its voting shares. For investors, VIEs matter because the controlling party’s financial results, debts and risks can appear in the controller’s reports even though ownership looks separate, so understanding VIEs helps assess true exposure, governance limits and transparency—like spotting a puppet controlled by strings rather than direct ownership.
cashless basis technical
"including on a cashless basis in the event"
An agreement executed on a cashless basis lets a holder convert or exercise a security (like options, warrants, or conversion rights) without paying money upfront; instead the holder receives a smaller number of shares equal in value to what the cash would have purchased. Think of trading a coupon for fewer slices of a cake rather than handing over cash for the full slice. For investors, it affects how much ownership and dilution occur and avoids immediate cash outlays.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What revenue and net loss did EHSI report for the first nine months of 2026?

EHSI reported $3.983 million in revenue and a $4.312 million net loss for the nine months ended September 30, 2026; the comparable 2025 net loss was $2.026 million.

What strategic alternatives is EHSI considering?

The board authorized management to consider equity or debt capital, asset sales, strategic financings, a merger, or disposition of all assets. The review has no timetable, may be terminated, and may end without a transaction.

What material weakness did EHSI identify?

The weakness involved independent verification of vendor-information changes and separate manager approval. The company said disclosure controls were ineffective at September 30, 2026, and management was developing remediation plans.

What are the terms of EHSI's notes and warrants with its CEO?

The notes are unsecured, bear 10% annual interest, and are due in July, August and October 2027; they carry a 2% prepayment penalty. Warrants cover up to 252,631 shares at $0.95, and the agreement permits additional investment on the same terms up to an aggregate of $1.5 million.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Q3 2026 --12-31 false 0001089815 false false false false 0 0 0.01 0.01 00010898152026-01-012026-09-30 thunderdome:item 00010898152026-07-012026-09-30 xbrli:shares 0001089815ehsi:NoteAgreementWarrantsMemberus-gaap:SubsequentEventMembersrt:ChiefExecutiveOfficerMember2026-10-01 iso4217:USD 0001089815us-gaap:SubsequentEventMembersrt:ChiefExecutiveOfficerMember2026-10-01 0001089815ehsi:BusinessEmailSecurityIncidentMember2026-07-012026-09-30 0001089815ehsi:NoteAgreementMember2026-07-31 iso4217:USDxbrli:shares 0001089815ehsi:NoteAgreementWarrantsMember2026-07-31 xbrli:pure 0001089815us-gaap:RelatedPartyMember2025-01-012025-12-31 0001089815us-gaap:RelatedPartyMember2026-07-012026-09-30 0001089815us-gaap:RelatedPartyMembersrt:ChiefExecutiveOfficerMember2025-01-012025-12-31 0001089815us-gaap:RelatedPartyMemberehsi:PrincipalFinancialOfficerMember2025-01-012025-12-31 0001089815us-gaap:RelatedPartyMemberehsi:BoardMembersMember2025-01-012025-12-31 0001089815us-gaap:RelatedPartyMemberehsi:ExecutiveDirectorMember2025-01-012025-12-31 0001089815us-gaap:RelatedPartyMemberehsi:DirectorLeimkuhlerMember2025-01-012025-12-31 0001089815us-gaap:RelatedPartyMemberehsi:DirectorStLawrenceMember2025-01-012025-12-31 0001089815us-gaap:RelatedPartyMember2025-12-31 00010898152025-01-012025-12-31 00010898152025-12-31 0001089815ehsi:PhysicianSupportSystemsPSSMember2025-10-31 0001089815ehsi:PhysicianSupportSystemsPSSMember2025-10-312025-10-31 00010898152025-07-012025-09-30 0001089815ehsi:NoteAgreementMember2026-09-30 0001089815ehsi:NoteAgreementWarrantsMember2026-09-30 utr:Y 00010898152026-09-30 00010898152025-10-31 0001089815ehsi:CBOncologyPartnersCBOPMember2025-12-31 0001089815ehsi:CBOncologyPartnersCBOPMember2026-09-30 0001089815ehsi:CBOncologyPartnersCBOPMember2025-01-012025-09-30 0001089815ehsi:CBOncologyPartnersCBOPMember2026-01-012026-09-30 0001089815ehsi:CBOncologyPartnersCBOPMember2025-01-012025-09-30 0001089815ehsi:CBOncologyPartnersCBOPMember2026-01-012026-09-30 0001089815ehsi:CBOncologyPartnersCBOPMember2026-09-30 00010898152025-01-012025-09-30 00010898152025-09-30 0001089815us-gaap:PrivatePlacementMember2023-11-272026-09-30 00010898152024-12-31 0001089815us-gaap:RetainedEarningsMember2026-09-30 0001089815ehsi:StockToBeIssuedMember2026-09-30 0001089815us-gaap:DeferredCompensationShareBasedPaymentsMember2026-09-30 0001089815us-gaap:AdditionalPaidInCapitalMember2026-09-30 0001089815us-gaap:CommonStockMember2026-09-30 0001089815us-gaap:RetainedEarningsMember2026-07-012026-09-30 0001089815us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-30 0001089815us-gaap:CommonStockMember2026-07-012026-09-30 0001089815us-gaap:DeferredCompensationShareBasedPaymentsMember2026-07-012026-09-30 00010898152026-06-30 0001089815us-gaap:RetainedEarningsMember2026-06-30 0001089815ehsi:StockToBeIssuedMember2026-06-30 0001089815us-gaap:DeferredCompensationShareBasedPaymentsMember2026-06-30 0001089815us-gaap:AdditionalPaidInCapitalMember2026-06-30 0001089815us-gaap:CommonStockMember2026-06-30 00010898152026-04-012026-06-30 0001089815us-gaap:RetainedEarningsMember2026-04-012026-06-30 0001089815us-gaap:DeferredCompensationShareBasedPaymentsMember2026-04-012026-06-30 00010898152026-03-31 0001089815us-gaap:RetainedEarningsMember2026-03-31 0001089815ehsi:StockToBeIssuedMember2026-03-31 0001089815us-gaap:DeferredCompensationShareBasedPaymentsMember2026-03-31 0001089815us-gaap:AdditionalPaidInCapitalMember2026-03-31 0001089815us-gaap:CommonStockMember2026-03-31 00010898152026-01-012026-03-31 0001089815us-gaap:RetainedEarningsMember2026-01-012026-03-31 0001089815us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-31 0001089815us-gaap:CommonStockMember2026-01-012026-03-31 0001089815us-gaap:DeferredCompensationShareBasedPaymentsMember2026-01-012026-03-31 0001089815us-gaap:RetainedEarningsMember2025-12-31 0001089815ehsi:StockToBeIssuedMember2025-12-31 0001089815us-gaap:DeferredCompensationShareBasedPaymentsMember2025-12-31 0001089815us-gaap:AdditionalPaidInCapitalMember2025-12-31 0001089815us-gaap:CommonStockMember2025-12-31 0001089815us-gaap:RetainedEarningsMember2025-09-30 0001089815ehsi:StockToBeIssuedMember2025-09-30 0001089815us-gaap:AdditionalPaidInCapitalMember2025-09-30 0001089815us-gaap:CommonStockMember2025-09-30 0001089815us-gaap:RetainedEarningsMember2025-07-012025-09-30 0001089815us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-30 0001089815us-gaap:CommonStockMember2025-07-012025-09-30 0001089815ehsi:StockToBeIssuedMember2025-07-012025-09-30 00010898152025-06-30 0001089815us-gaap:RetainedEarningsMember2025-06-30 0001089815ehsi:StockToBeIssuedMember2025-06-30 0001089815us-gaap:AdditionalPaidInCapitalMember2025-06-30 0001089815us-gaap:CommonStockMember2025-06-30 00010898152025-04-012025-06-30 0001089815us-gaap:RetainedEarningsMember2025-04-012025-06-30 00010898152025-03-31 0001089815us-gaap:RetainedEarningsMember2025-03-31 0001089815ehsi:StockToBeIssuedMember2025-03-31 0001089815us-gaap:AdditionalPaidInCapitalMember2025-03-31 0001089815us-gaap:CommonStockMember2025-03-31 00010898152025-01-012025-03-31 0001089815us-gaap:RetainedEarningsMember2025-01-012025-03-31 0001089815us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31 0001089815us-gaap:CommonStockMember2025-01-012025-03-31 0001089815ehsi:StockToBeIssuedMember2025-01-012025-03-31 0001089815us-gaap:RetainedEarningsMember2024-12-31 0001089815ehsi:StockToBeIssuedMember2024-12-31 0001089815us-gaap:AdditionalPaidInCapitalMember2024-12-31 0001089815us-gaap:CommonStockMember2024-12-31 00010898152026-11-14 0001089815ehsi:EliteHealthPlanIncMember2026-01-012026-09-30 0001089815ehsi:PhysicianSupportSystemsPSSMember2026-01-012026-09-30
 

 

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026

or

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

For the transition period from                to                .

 

Commission file number: 0-15586

 

Elite Health Systems Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

47-5370333

(State or other jurisdiction of

(I.R.S. Employer

incorporation or organization)

Identification No.)

 

1131 W 6th Street, Ontario, CA 91762

(Address of principal executive offices)

 

(909) 657-2705

(Registrant's telephone number)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes ☒         No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes ☒         No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer     ☐

Accelerated filer     ☐

Non-accelerated filer     ☐

Smaller reporting company     ☒

 

Emerging Growth Company     ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes ☐         No ☒

 

The number of shares of the registrant’s common stock, $0.01 par value, outstanding as of November 14, 2026 was 28,682,989.

 

 

  

 

Table of Contents

 

PART I - FINANCIAL INFORMATION

3

Item 1.  Financial Statements

3

Item 2.  Management Discussion and Analysis of Financial Condition and Results of Operations.

16

Item 3.  Quantitative and Qualitative Disclosures About Market Risk.

20

Item 4.  Controls and Procedures

20

PART II – OTHER INFORMATION

22

Item 1.  Legal Proceedings

22

Item 2.  Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities Unregistered Sales of Equity Securities and Use of Proceeds

22

Item 3.  Defaults Upon Senior Securities

22

Item 4.  Submission of Matters to a Vote of Security Holders

22

Item 5.  Other Information

22

Item 6.  Exhibits

23

SIGNATURES

24

 

 

  

 

Item 1. Financial Statements

 

ELITE HEALTH SYSTEMS INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 

   

September 30,

   

December 31,

 
   

2026

   

2025

 
   

(Unaudited)

   

(Audited)

 
ASSETS                 

Current assets:

               

Cash and cash equivalents

  $ 740,000     $ 3,758,000  

Other current assets

    284,000       296,000  

Accounts receivable from related parties

    333,000       330,000  

Stock subscriptions receivable

    100,000       100,000  

Total other assets

    1,457,000       4,484,000  
                 

Non-current assets

               

Goodwill

    984,000       984,000  

Website development costs

    53,000       71,000  

Capitalized software under development

    961,000       1,081,000  

Fixed asset

    17,000       7,000  

Operating lease right-of-use asset

    3,000       37,000  

Total property and equipment

    2,018,000       2,180,000  
                 

TOTAL ASSETS

  $ 3,475,000     $ 6,664,000  
                 

LIABILITIES

               

Operating lease right-of-use liability - current portion

  $ 3,000     $ 38,000  

Accounts payable and accrued expenses

    1,080,000       922,000  

Claims incurred but not reported

    80,000       -  

Customer advances from related parties

    158,000       380,000  

Total current liabilities

    1,321,000       1,340,000  

Note Payable

    755,000          

Guarantee liability

    11,000       11,000  

Total liabilities

    2,087,000       1,351,000  
                 
EQUITY                 

Common stock - par value $.01; 50,000,000 shares authorized; 28,682,989 and 28,521,620 shares issued and outstanding at September 30, 2026 and December 31, 2025.

    287,000       285,000  

Stock based compensation

    178,000       66,000  

Additional paid-in capital

    17,484,000       17,211,000  

Accumulated deficit

    (16,561,000 )     (12,249,000 )

Total stockholders' equity

    1,388,000       5,313,000  
                 

TOTAL LIABILITIES AND EQUITY

  $ 3,475,000     $ 6,664,000  
 

See accompanying notes to the consolidated financial statements

 

3

 

 

LITE HEALTH SYSTEMS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   

Three Months Ended

   

Nine Months Ended

 
   

September 30,

   

September 30,

 
   

2026

   

2025

   

2026

   

2025

 
                                 

Income

                               

Revenue

  $ 1,276,000     $ -     $ 3,983,000     $ -  

Cost of revenue

    1,147,000       -       3,569,000       -  
      129,000       -       414,000       -  
                                 

Costs and expenses:

                               

Selling, general and administrative

    1,386,000       1,165,000       4,511,000       2,036,000  

Total

    1,386,000       1,165,000       4,511,000       2,036,000  
                                 

Operating loss

    (1,257,000 )     (1,165,000 )     (4,097,000 )     (2,036,000 )
                                 

Total other income (expense)

                               

Interest Income

    8,000       -       20,000       -  

Interest expense

    (4,000 )     4,000       (2,000 )     10,000  

Security incident loss

    (233,000 )             (233,000 )        

Total other (expense)

    (229,000 )     4,000       (215,000 )     10,000  
                                 

Net Income (loss)

  $ (1,486,000 )   $ (1,161,000 )   $ (4,312,000 )   $ (2,026,000 )
                                 
                                 

Basic and diluted net Income (loss) per share

  $ (0.05 )   $ (0.05 )   $ (0.15 )   $ (0.09 )
                                 

Weighted average common shares outstanding, basic and diluted

    28,683,598       21,726,722       28,636,935       21,408,642  

 

The accompanying notes to condensed consolidated financial statements are an integral part hereof. 

 

4

 

 

ELITE HEALTH SYSTEMS INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF  EQUITY

(UNAUDITED)

 

   

Common Stock

                                         
   

Number

           

Additional

                   

(Accumulated

         
   

of

           

Paid-In

   

Stock-based

   

Stock to

   

Deficit)

         
   

Shares

   

Amount

   

Capital

   

Compensation

   

Be Issued

   

Retained Earnings

    Total Equity  
                                                         

Balance - December 31, 2024

    19,984,924     $ 200,000     $ 8,185,000             $ 238,000     $ (4,445,000 )   $ 4,178,000  

Issued from prior period

                                    (238,000 )                

Issuance of common stock

    1,425,000       14,000       698,000                               712,000  

Net loss for the quarter ended March 31, 2025

                                            (424,000 )     (424,000 )

Balance -March 31, 2025

    21,409,924     $ 214,000     $ 8,883,000             $ -     $ (4,869,000 )   $ 4,228,000  

Net loss for the quarter ended June 30, 2025

                                            (441,000 )     (441,000 )

Balance -June 30, 2025

    21,409,924     $ 214,000     $ 8,883,000             $ -     $ (5,310,000 )   $ 3,787,000  

Stock to be issued

                    -               1,890,000               1,890,000  

Issuance of common stock

    530,000       6,000       498,000                               504,000  

Net loss for the quarter ended September 30, 2026

    -                                       (1,161,000 )     (1,161,000 )

Balance -September 30, 2025

    21,939,924     $ 220,000     $ 9,381,000             $ 1,890,000     $ (6,471,000 )   $ 5,020,000  
                                                         

Balance -December 31, 2025

    28,521,620     $ 285,000     $ 17,211,000     $ 66,000     $ -     $ (12,249,000 )   $ 5,313,000  

Stock-based compensation expense

                            41,000                       41,000  

Net loss for the quarter ended March 31, 2026

    -       -       -                       (1,294,000 )     (1,294,000 )

Balance - March 31, 2026

    28,521,620     $ 285,000     $ 17,211,000       107,000     $ -     $ (13,543,000 )   $ 4,060,000  

Stock-based compensation expense

                            41,000                       41,000  

Shares pending issuance

                                                       

Net loss for the quarter ended June 30, 2026

    -                                       (1,532,000 )     (1,532,000 )

Balance - June 30, 2026

    28,521,620     $ 285,000     $ 17,211,000       148,000     $ -     $ (15,075,000 )   $ 2,569,000  

Stock-based compensation expense

                            30,000                       30,000  

Issuance of common stock

    161,369       2,000       151,000                               153,000  

Issuance of warrant

                    122,000                               122,000  

Net loss for the quarter ended September 30, 2026

    -                                       (1,486,000 )     (1,486,000 )

Balance - September 30, 2026

    28,682,989     $ 287,000     $ 17,484,000       178,000     $ -     $ (16,561,000 )   $ 1,388,000  

 

See accompanying notes to the consolidated financial statements

 

5

 

 

ELITE HEALTH SYSTEMS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 

(UNAUDITED)

 

   

Nine Months Ended

 
   

September 30,

 
   

2026

   

2025

 
                 

Cash flows from operating activities:

               

Net loss

  $ (4,312,000 )   $ (2,026,000 )

Adjustments to reconcile net loss to net cash used in operating activities:

               

Amortization and Depreciation

    141,000       -  

Amortization of operating lease right-of-use asset

    34,000       26,000  

Stock-based compensation expense

    112,000       504,000  

Accounts receivable

    (3,000 )     -  

Other current assets

    12,000       (274,000 )

Stock subscription receivable

    -       175,000  

Accounts payable and accrued expenses

    158,000       173,000  

Claims incurred but not reported

    80,000       -  

Operating lease right-of-use liability

    (35,000 )     (26,000 )

Customer advances from related parties

    (222,000 )     -  

Net cash used in operating activities

    (4,035,000 )     (1,448,000 )

Cash flows from investing activities:

               

Receipt of distributions outstanding

    -       11,000  

Purchase of fixed asset and website development cost

               

Capitalization of software development costs

    (13,000 )     (992,000 )

Net cash used in investing activities

    (13,000 )     (981,000 )
                 

Cash flows from financing activities:

               

Sale of shares (not yet issued)

    -       1,890,000  

Issuance of notes payable

    755,000       -  

Issuance of common stock and warrants

    275,000       475,000  

Net cash provided by financing activities

    1,030,000       2,365,000  
                 

Net change in cash and cash equivalents

    (3,018,000 )     (64,000 )

Cash and cash equivalents - beginning of period

    3,758,000       4,034,000  

Cash and cash equivalents - end of period

  $ 740,000     $ 3,970,000  

 

The accompanying notes to condensed consolidated financial statements are an integral part hereof

 

6

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

 

 

Note A - Basis of Preparation

 

Organization and Business

 

Elite Health Systems Inc., formerly U.S. NeuroSurgical Holdings, Inc., is focused on improving and providing access to healthcare and offering other healthcare related services through its wholly-owned subsidiaries, Elite Health Plan, Inc. and Physician Support Systems Inc. (“PSS”). As used herein, unless the context indicates otherwise, the term "Company" and "Registrant" means Elite Health Systems Inc. and its wholly-owned subsidiaries, Elite Health Systems Holdings Inc. (“EHSH”), and the wholly-owned subsidiaries of EHSH, USN Corona, Inc., Elite Health Plan, Inc., Elite Health Plan of Nevada, Inc. and PSS.

 

 

Company Background. 

 

The Company is focused on improving and providing access to healthcare and offering other healthcare related services. Through its subsidiaries the Company is developing and offering one or more Medicare Advantage plans and providing healthcare management solutions to physician and other health groups. 

  

In October  2021, the Company’s wholly-owned subsidiary, Elite Health Systems Holdings Inc. (“EHSH”), acquired all of the outstanding shares of capital stock of Elite Health Plan, Inc., a California corporation and, in exchange therefor, the former holders of which were issued newly-issued shares of EHSH, which at the time of the transaction represented 15% of the outstanding shares of EHSH.  In November 2023, the Company then entered into a Share Exchange Agreement with the holders of these minority interests in EHSH and as a result of this transaction EHSH became a wholly-owned subsidiary of the Company and the former minority holders of EHSH became owners in the aggregate of 15% of the Company.   

  

Beginning in 2021, the Company through its subsidiaries dedicated resources to exploring the regulatory requirements and timelines to apply and secure licenses to operate a Medicare Advantage plan in California and Nevada. EHSH formed Elite Health Plan of Nevada, Inc. (“Elite Nevada”) to apply for a license to operate a Medicare Advantage plan in Nevada while Elite Health Plan, Inc. pursued a plan to establish a Medicare Advantage plan in California. The Company then determined it would be more expeditious to apply and secure a license in California and then, if and when appropriate, apply for a license in Nevada. Elite Health applied for a Knox-Keene license to offer managed health care plans in California in 2024, which was approved by the State of California and CMS the Centers for Medicare and Medicaid Services “(CMS”) in 2025.  Elite Health and Elite Health Plan of Nevada, Inc. are wholly-owned subsidiaries of EHSH, are managed and operated in a similar manner.  In California, Elite Health has developed a network of providers who are well-versed in Medicare Advantage plans and addressing the healthcare needs of seniors in the communities in which they practice, and following licensure began onboarding members of its Medicare Advantage Plans in October 2025. Though it may do so in the future, Elite Health Plan of Nevada, Inc., at this time, has not taken any further steps to advance or submit an application for a Knox-Keene license to offer managed health care plans in Nevada.   Elite Health began reporting member revenue on January 1, 2026. There can be no assurance that the Company and Elite Health will be successful in maintaining the necessary licenses to operate Medicare Advantage plans in any jurisdiction or be effective in establishing the network of providers and developing the systems required to operate a managed care business. 

 

In November 2025 the Company purchased all the outstanding stock of PSS from its former shareholders and began operations as part of EHSI providing a suite of tailored healthcare management solutions to medical practices that enhance operational efficiency, compliance, and patient care.

  

7

 

The Company’s headquarters are now located at 1131 W 6th Street, Suite 225, Ontario, CA  91762 and its telephone number is (949) 249-1170.  

 

Recent Accounting Pronouncements

 

FASB ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures 

  

The FASB issued ASU 2023-07 on November 27, 2023, which is intended to improve reportable segment disclosure requirements. Under previous guidance, while entities were required to disclose segment revenue and profit or loss, there has been limited disclosure around the reporting of segment expenses. In addition to enhanced disclosures about significant segment expenses, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company has adopted the requirements of the expanded segment disclosures as of December 31, 2025. 

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, aimed at increasing transparency in income tax reporting. It requires entities to disaggregate their effective tax rate reconciliation (using percentages and amounts) and income taxes paid, breaking them down by specific categories and jurisdictions. The pronouncement is effective for fiscal periods beginning after December 15, 2024. The Company has adopted the additional disclosure as of December 31, 2025. 

 

In September 2025, FASB ASU 2025-06 modernizes internal-use software accounting by replacing rigid "project stage" rules with a principles-based framework aligned with agile development. It streamlines capitalization, integrates website development costs, and mandates clearer disclosures, effective for annual periods beginning after Dec. 15, 2027.  The Company is currently evaluating the impact of ASU 2025-06. 

  

The Company applies the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 810, Consolidation to noncontrolling interests in consolidated financial statements.  The guidance requires noncontrolling interests to be reported as a component of equity separate from the parent’s equity and purchases and sales of equity interests that do not result in a change in control, to be accounted for as equity transactions.  In addition, net (loss) income attributable to noncontrolling interests are to be included in net (loss) income and, upon a loss of control, the interest sold, as well as any interest retained, is to be recorded at fair value, with any gain or loss recognized in net (loss) income. 

  

All amounts are shown in nearest thousands in the Consolidated Financial Statements and accompanying notes therein. 

 

Liquidity and Going Concern

 

In the nine months ended September 30, 2026, the Company incurred a net loss of $4,312,000 compared to $2,026,000 in the same period of fiscal year 2025. The Company has received state and Federal approval to operate as a Medicare Advantage plan and began operating as a Medicare Advantage plan on January 1, 2026. As a result, it recorded no revenue from its health plan in 2025 and has significant expenses. The Company has funded operations through the sale of common stock. The Company had an accumulated deficit in stockholders’ equity of $16,561,000 and $12,249,000 at September 30, 2026 and December 31, 2025, respectively; cash and cash equivalents of $740,000 and $3,758,000 at September 30, 2026 and December 31, 2025, respectively; and working capital of $136,000 and $3,144,000 at September 30, 2026 and December 31, 2025, respectively. In addition, the Company currently does not have access to capital through a line of credit nor other readily available sources of capital. Together, these factors raised substantial doubt regarding the Company’s ability to continue as a going concern at September 30, 2026.

 

8

 

However, management has considered its plans to continue the Company as a going concern, concentrating on the establishment and operation of managed health care plans. The Company raised gross proceeds of approximately $14 million in support of this business opportunity through the sale of its Common Stock in a private placement and believes it has access to additional capital in 2026. However, the Company is operating in a highly competitive business environment with complex regulatory and operational challenges. In order to be successful, the Company must significantly increase its health care membership and hire additional key members of management, both of which will take significant capital and time. As a result, the Board of Directors authorized management to consider and pursue strategic alternatives involving the Company. The strategic review authorized by the Company’s Board of Directors will include consideration of potential equity or debt capital, selling certain assets, including one or more of its operating businesses, or other strategic financings or transactions, such as a merger or disposition of all of its assets. No timetable has been established to achieve any transaction and there can be no assurance that any strategic transaction, if implemented, will result or result in an increase in stockholder value. The Company may terminate its review at any time and may ultimately determine not to pursue a strategic transaction.

 

Management believes its plan alleviates the substantial doubt and that it will be successful in its planned business initiatives and will be able to continue as a going concern through at least the next twelve months. However, failure to consummate a strategic transaction, including a financing, merger, sale or disposition of all or substantially all of its assets, or other strategic alternative, could have a material adverse effect on the Company’s liquidity, financial condition and ability to continue operations. There can be no assurance that any such transaction will be completed on acceptable terms, or at all. 

 

Pursuant to accounting requirements of the Securities and Exchange Commission applicable to quarterly reports on Form 10-Q, the accompanying Condensed Consolidated Financial Statements and notes do not include all disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. Accordingly, these statements should be read in conjunction with the Company’s most recent annual Consolidated Financial Statements.

 

Consolidated results of operations for interim periods are not necessarily indicative of those to be achieved for full fiscal years. The only change to the Company’s equity in the three months ended September 30, 2026 and 2025 was net loss for the periods, issuance of common stock and stock based compensation.

 

The Company applies the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 810, Consolidation to noncontrolling interests in consolidated financial statements. The guidance requires noncontrolling interests to be reported as a component of equity separate from the parent’s equity and purchases and sales of equity interests, that do not result in a change in control, to be accounted for as equity transactions.  In addition, net (loss) income attributable to noncontrolling interests are to be included in net (loss) income and, upon a loss of control, the interest sold, as well as any interest retained, is to be recorded at fair value, with any gain or loss recognized in net (loss) income.

 

The Company recognizes revenue in accordance with two different accounting standards: 1) Topic 606 and 2) Accounting Standards Codification (“ASC”) Topic 842, Leases.

 

Basic loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The numerator for the calculation of basic and diluted earnings per share is net loss and the denominator is the weighted-average number of common shares outstanding during the period.

 

9

 

The tables below present financial information associated with our leases.

 

 

Classification

 

September 30,

 
     

2026

   

2025

 
Assets                  

Long-term

                 

Operating lease assets

Operating lease right-of-use asset

  $ 3,000     $ 46,000  

Total leased assets

  $ 3,000     $ 46,000  
                   

Liabilities

                 

Current

                 

Operating lease liabilities

Operating lease right-of-use liability - current portion

  $ 3,000     $ 37,000  
                   

Long-term

                 

Operating lease liabilities

Operating lease right-of-use liability - net of current portion

  $ -     $ 10,000  

Total lease liabilities

  $ 3,000     $ 47,000  
                   

Lease Cost

                 

Operating lease cost

Selling, general and administrative

  $ 31,000     $ 26,000  

Net lease expense

  $ 31,000     $ 26,000  

 

   

Operating

lease

 

Maturity of lease liabilitizes

       

2026

    3,000  

Total

  $ 3,000  

Less amount representing interest

    -  

Present value of lease liabilities

  $ 3,000  

Discount rate

    4.140 %

 

  

 

Note B - CB Oncology Partners

 

CBOP was organized September 1, 2017, to acquire the rights of a new center in Cutler Bay, FL. Effective November 15, 2019, CBOP assumed, a loan with BB&T bank, that it had entered into in order to finance the purchase of equipment and build out of the new center, as well as the associated property and equipment. The Company and other investors were guarantors of the loan. In July 2020 CBOP and BB&T agreed to a reduction in the monthly payments for the life of the loan and an extension in the term of the loan to July of 2027. 

  

During the years ended December 31, 2025 and 2024, the Company did not lend any additional funds to CBOP. This equity investment was fully impaired due to Equity Method accounting. These allowances and write-offs were recorded as losses from investments in unconsolidated entities.

 

For the nine-months ended September 30, 2026 the Company’s equity in loss of CBOP was $84,000compared to an equity in loss of $187,000 during the same period in 2025, but was not recorded due to prior losses. 

 

Due to loans made to CBOP, CBOP is considered to be a variable interest entity of the Company. However, as the Company is not deemed to be the primary beneficiary of CBOP, since it does not have the power to direct the operating activities that most significantly affect CBOP’s economic performance, the entity is not consolidated, but certain disclosures are provided herein.

 

The Company was approached by one of the investors in CBOP where the investor would payoff the outstanding loan, releasing the Company of its guarantee in exchange for the Company’s ownership interest in CBOP. The Company has evaluated the proposal and in return wrote off the remaining value of amounts due the Company from CBOP of $525,000. The Company does not expect any further liability from the same.

 

10

 

The following table presents the summarized financial information of CBOP:

 

CBOP Condensed Income Statement Information

 

   

Nine Months Ended

 
    September 30,  
   

2026

   

2025

 
                 

Patient revenue

  $ 1,108,000     $ 1,056,000  
                 

Net income (loss)

  $ (278,000 )   $ (620,000 )
                 

EHSHI's equity in income (loss) of CBOP

  $ (84,000 )   $ (187,000 )

 

CBOP Condensed Balance Sheet Information        

 

   

September 30,

   

December 31,

 
   

2026

   

2025

 
                 

Current assets

  $ 445,000     $ 348,000  
                 

Noncurrent assets

    728,000       1,185,000  
                 

Total assets

  $ 1,173,000     $ 1,533,000  
                 

Current liabilities

  $ 4,489,000     $ 4,648,000  
                 

Noncurrent liabilities

    3,477,000       3,263,000  
                 

Deficit

    (6,793,000 )     (6,378,000 )
                 

Total liabilities and deficit

  $ 1,173,000     $ 1,533,000  

 

  

 

Note C – Elite Health

 

Background. Elite Health Plan was formed in 2017 with the purpose of establishing a managed care organization that will develop and operate Medicare Advantage plans for seniors in California. In addition to obtaining the required authorizations, including a Knox-Keene license from California’s Department of Managed Health Care (“DMHC”), necessary for the operation of full service health plans in California, and approval from the Centers for Medicare & Medicaid Services (“CMS”), the Company is considering engaging in related business and health services to support this mission. 

  

Medicare Advantage plans are offered by private companies and are regulated by the federal government and licensed by the state in which those companies operate. Now that its initial plans are approved for 2026 to operate in the California counties of San Bernadino, Riverside, and Los Angeles, it plans to expand the types of plans it provides to include special needs plans with the objective of addressing the growing number of Medicare eligible seniors in those markets and growing the number of members in its plans through a combination of marketing and other strategies. The Company ultimately expects to apply to the State of Nevada and other states. Because of the collective experience of its founders and affiliates as physicians, software executives, and health plan administrators, we believe that EHP will be positioned to bring to California and Nevada a comprehensive, community-based and cost-effective health care management service solution for these communities. 

  

Filing in California.  The Company initially applied for a license to operate a Medicare Advantage plan in Nevada.  However, the Company determined that a reciprocity agreement between California and Nevada would result in a more expedient path to licensing in Nevada upon the securing of approvals in California first. For this reason, Elite Health applied for and obtained the Knox-Keene license in California, and secured necessary approvals from CMS in 2025.  The Company began operating as a Medicare Advantage plan in January 2026. Such license is subject to many attestations and audits and as a result there can be no assurance that such license can be maintained.   

 

11

  

 

Note D – 2025 Equity Incentive Plan 

  

The Company’s stockholders approved the 2025 Equity Incentive Plan at a special meeting of stockholders on October 31, 2025. The plan provides for an aggregate maximum of 4,500,000 shares of common stock to be issued under the plan. At December 31, 2025, 398,000 options were outstanding under the plan with no options exercisable. The Company recorded non-cash equity expense of $30,000 and $0 in the quarters ended September 30, 2026 and 2025, respectively. At September 30, 2026 and December 31, 2025 there was $166,000 and $297,000, respectively, of unamortized expense to be recorded over 1.8 years. 

  

   

Three Months Ended September 30,

 
   

2026

   

2025

 

Expected life (in years)

    5.5       -  

Expected volatility

    139.3 %     -  

Dividend yield

    0.0 %     -  

 

  

   

Number of

Shares

   

Weighted

Average

Exercise

Price

   

Aggregate

Fair Market

Value

   

Weighted

Average

Remaining

Contractual

Term

 

Outstanding at December 31, 2025

    398,000     $ 0.95     $ 0.86       9.6  

Granted

    -       -       -       -  

Forfeited or expired

    -       -       -       -  

Outstanding at September 30, 2026

    398,000     $ 0.95     $ 0.86       8.9  

Exercisable at September 30, 2026

    198,349     $ 0.95     $ 0.86       8.9  

  

 

Note E - Subordinated Notes Payable and Attached Warrants

 

On July 31, 2026, the independent members of the board of directors of Elite Health Systems Inc. (the “Registrant”) approved entering into a subordinated notes and warrants agreement (the “Note Agreement”) with Dr. Prasad Jeereddi, the Company’s CEO and chair. The notes were funded in July, August and October, 2026 for a total of $1.2 million and is due on the last day of the months of July, August and October, 2027, is unsecured, carries an interest rate of 10% per annum and includes a 2% prepayment penalty.

 

The Company simultaneously entered into warrant agreements with Dr. Jeereddi to purchase up to 252,631 shares of the Company’s common stock at an exercise price of $0.95 per share spread over the maturity dates of the end of July, August and September, 2031. The warrants may be exercised in whole or in part at any time up to the maturity date, including on a cashless basis in the event the shares issuable pursuant to the warrant are not registered at the point of exercise. Shares issuable pursuant to the warrant are not currently registered and accordingly carry certain restrictions on transfer.

 

The Note Agreement provides that the Registrant may accept additional investment, on the same terms, of up to an aggregate of $1.5 million.

 

The Company accounted for the notes payable and warrants by allocating the proceeds between the notes payable and warrants. Accordingly, the Company valued the warrants using a Black Scholes valuation model and allocated the portion of the proceeds equaling the valuation to warrants with the difference to notes payable. As a result $999,000 was allocated to notes payable and $201,000 was allocated to warrants. The value of the notes payable will be accreted to is face value of $1.2 million over the life of the notes in addition to non-cash interest that will be added to the face value of the notes payable and due at maturity.

 

12

  

 

Note F – Income Taxes

 

The Company’s income tax rate, which includes federal and state income taxes, was 0%, for each of the three months ended September 30, 2026, and 2025, respectively.

 

 

 

NOTE G – Acquisition of Physician Support Systems, Inc.

 

Following approval of the Company’s stockholders at a meeting held on October 31, 2025, the Company completed its acquisition of all of the outstanding shares of Physician Support Systems, Inc. from its stockholders in exchange for 3,158,000 new shares of its common stock. A Special Committee of the Board, composed entirely of disinterested directors of the EHSI Board, considered a number of factors that it viewed as supporting its decision to approve the Acquisition Agreement, including: 

  

 

●

The Company believes the Acquisition will strengthen the Company’s health experience, access to providers and management team; 

 

●

PSS is an operating business with revenue, creating a stronger set of financial statements of the Company; 

 

●

The Board believes the addition of an operating business with significant provider connections and management expertise will benefit the Company’s business and thus the stockholders of the Company; 

 

●

The Board believes the combined enterprise, the Company with PSS, will have greater access to capital and recognition by the public markets; 

 

●

A stronger financial and operating company will likely be viewed positively by State and Federal regulators and the commercial insurance and healthcare markets; 

 

●

The Special Committee believes the terms of the transaction are favorable to the Company; 

  

 

The Company recorded the acquired tangible and intangible assets and liabilities assumed based on their estimated fair values. The company attributed all the intangible assets to assembled workforce, expected synergies, strategic positioning, and other future economic benefits that do not meet the contractual or separability for recognition as distinct intangible assets under ASC 805. Accordingly, management concluded that all the intangible assets be allocated to goodwill. 

  

The company assessed the significance of the acquisition and determined it did not meet the definition of a significant subsidiary as defined in Reg S-X, Rule 1-02(w). Accordingly, no proforma results are provided. 

  

13

 

The following table summarizes the fair values of the assets acquired and liabilities assumed on the date of the acquisition.

  

   

Fair Value

 

Assets acquired:

       

Due from clients

  $ 783,127  

Prepaid expense

    6,581  

Goodwill

    4,962,304  

Total assets acquired

    5,752,012  
         

Liabilities assumed:

       

Due to clients

    612,752  

Accounts payable

    58,887  

Credit cards and accrued liabilities

    438,113  

Total liabilities assumed

    1,109,752  

Total purchase price

  $ 4,642,260  

  

  

 

Note H – Goodwill impairment 

  

Goodwill and intangible assets that have indefinite useful lives are recorded at cost and are not amortized but, instead, tested at least annually for impairment. The Company assesses the impairment of goodwill on an annual basis or whenever events or changes in circumstances indicate that the fair value of these assets is less than the carrying value. The Company determined that the loss of a customer of PSS was a circumstance that required a review of the carrying value of goodwill associated with the acquisition of PSS, despite the fact that the acquisition was completed just two months prior to the balance sheet date. As noted above in footnote G, the value considered by the Special Committee of the Board was primarily related to assembled workforce, expected synergies, strategic positioning, and other future economic benefits which are not easily quantified in a discounted cash flow analysis. The Company assessed the cash flow of the stand-alone PSS business and considered the going concern, lack of available debt capacity and anticipated equity returns an investor would require in a start-up business in evaluating the weighted average cost of capital in discounting such cash flows to present value. As a result, the Company adjusted goodwill to a newly calculated fair value of $984,000 and recorded the resulting impairment charge to goodwill of $3,978,000 at December 31, 2025. There were no events or changes in circumstances to indicate that the fair value of these assets is less than the carrying value at September 30, 2026.

 

 

Note I – Segment Reporting

 

The Company applies ASC 280, Segment Reporting, in determining reportable segments for its financial statement disclosure. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer (“CEO”). The Company has determined that it operates two operating segments, EHP and PSS, but that these segments meet the criteria for aggregation for reporting purposes as one reportable segment. 

 

14

  

 

Note J – Transactions with Related Parties

 

The Company recorded compensation with directors and officers of the Company for the year ended December 31, 2025 consisting of stock grants valued at $0.95 per share of 40,000 for each of directors St. Lawrence and Leimkuhler; 75,000 for Executive Director Ms. Reeher; and 375,000 for CEO and Board Chair, Dr. Jeereddi. Additionally, the Company awarded stock options to the Board of 25,000 each, or prorated for new director Dr. Policherla, 75,000 each for Mr. Minor and Ms. Reeher and 125,000 for Dr. Jeereddi. 

  

During the years ended December 31, 2025 and the quarter ended September 30, 2026, the Company compensated PSS for services of Ms. Reeher and others as well as the sharing of rental space and other services. Dr. Jeereddi was the majority owner of PSS and Ms. Reeher was the Executive Director. PSS was acquired by the Company on November 4, 2025. In addition, each of the customers of PSS are companies with either a familial and or management relationship to Dr. Jeereddi. Accordingly, revenue associated with PSS of $1,097,000 and $3,269,000 reported for the quarter ended September 30, 2026 and the year ended December 31, 2025, respectively, comes from related parties. 

 

On July 31, 2026, the independent members of the board of directors of Elite Health Systems Inc. (the “Registrant”) approved entering into a subordinated notes and warrants agreement (the “Note Agreement”) with Dr. Prasad Jeereddi, the Company’s CEO and chair. The notes were funded in July, August, and October, 2026 for a total of $1.2 million and is due on the last day of the months of July, August, and October, 2027, is unsecured, carries an interest rate of 10% per annum and includes a 2% prepayment penalty.

 

The Company simultaneously entered into warrant agreements with Dr. Jeereddi to purchase up to 252,631 shares of the Company’s common stock at an exercise price of $0.95 per share spread over the maturity dates of the end of July, August and October, 2031. The warrants may be exercised in whole or in part at any time up to the maturity date, including on a cashless basis in the event the shares issuable pursuant to the warrant are not registered at the point of exercise. Shares issuable pursuant to the warrant are not currently registered and accordingly carry certain restrictions on transfer.

 

The Note Agreement provides that the Registrant may accept additional investment, on the same terms, of up to an aggregate of $1.5 million.

 

 

Note K — Subsequent Events / Loss Contingency and Cybersecurity Incident

 

During third quarter of 2026, the Company experienced a business email compromise (BEC) security incident in which an unauthorized third party impersonated a vendor and fraudulently induced the Company to remit payments totaling approximately $233,000. Upon discovering the incident, management immediately initiated an internal investigation, notified the appropriate financial institutions and insurance companies, and implemented enhanced internal controls over vendor payment verification.

 

In accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), specifically Accounting Standards Codification (ASC) 450, Contingencies, the Company recognized the full $233,000 loss within Other Expenses on the Statement of Operations for the period ended September 30, 2026.

 

The Company maintains cyber and crime insurance coverage and has submitted a claim seeking reimbursement for the fraudulent transfer, net of applicable policy deductibles. While management expects to recover a substantial portion of the loss through its insurance coverage, under ASC 450-30, Gain Contingencies, insurance recoveries are recognized in the financial statements only when realization of the claim is deemed probable (defined as likely to occur) and the amount is reasonably estimable. Because the insurer’s formal coverage determination remains pending as of the date these financial statements were available to be issued, recovery is not yet considered probable under the applicable accounting standard. Accordingly, no insurance recovery receivable or offsetting gain has been recorded in the financial statements as of September 30, 2026. Any future insurance proceeds will be recognized in the period in which the contingency is resolved or recovery becomes probable.

 

15

  

 

Note L – Subsequent Events

 

As discussed in Note J, the Company issued notes payable and warrants to Dr. Prasad Jeereddi, CEO. One of those transactions was completed on October 1, 2026, including a note payable of $350,000 and warrant for the purchase of 73,684 shares of common stock.

 

 

Item 2.  Management Discussion and Analysis of Financial Condition and Results of Operations.

 

Critical Accounting Policies

 

The Condensed Consolidated Financial Statements of Elite Health Systems Inc. and subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America. As such, some accounting policies have a significant impact on amounts reported in the Condensed Consolidated Financial Statements. A summary of those significant accounting policies can be found in Note B to the Consolidated Financial Statements, in our 2025 Annual Report on Form 10-K. In particular, judgment is used in areas such as determining and assessing possible asset impairments, including investments in, and advances, to unconsolidated entities.

 

The following discussion and analysis provides information which the Company’s management believes is relevant to an assessment and understanding of the Company’s results of operations and financial condition. This discussion should be read in conjunction with the Condensed Consolidated Financial Statements and notes thereto appearing elsewhere herein.

 

Recent events

 

None

 

Results of Operations

 

Three Months ended September 30, 2026, Compared to Three Months Ended September 30, 2025

 

Revenue related to Medicare Advantage payments from CMS was $179,000 and $0, for the three months ended September 30, 2026, and 2025, respectively. The amount in 2026 was due to the fact that Elite began serving Medicare Advantage policy holders in 2026. Policy expenses for the same period was $194,000 and $0 respectively, primarily due to medical and capitated payments associated with serving Medicare Advantage policy holders.

 

Revenue attributed to services was $1,097,000 and $0 for the three months ended September 30, 2026, and 2025, respectively due to the acquisition of PSS. Cost of revenue related to services for the same period was $953,000 and $0, respectively.

 

Selling, general, and administrative expenses of $1,386,000 for the third quarter of 2026 were 19% higher than the $1,165,000 incurred during the comparable period in 2025, due mostly to the continued investment in Elite.

 

During the three months ended September 30, 2026 and 2025, the Company recorded no income tax benefit or provision.

 

16

 

For the three months ended September 30, 2026, the Company reported a net loss of $1,486,000 as compared to $1,161,000 for the same period a year earlier. The net loss was primarily due to the continued investment in Elite above the generation of any revenue.

 

Nine months ended September 30, 2026, Compared to Nine months ended September 30, 2025

 

Revenue related to Medicare Advantage payments from CMS was $513,000 and $0, for the nine months ended September 30, 2026, and 2025 respectively. The amount in 2026 was due to the fact that Elite began serving Medicare Advantage policy holders in 2026. Medical and capitated expenses for the same period was $581,000 and $0 respectively, also due to serving Medicare Advantage policy holders.

 

Revenue attributed to services was $3,470,000 and $0 for the nine months ended September 30, 2026, and 2025, respectively due to the acquisition of PSS. Cost of revenue related to services for the same period was $3,569,000 and $0, respectively.

 

Selling, general, and administrative expenses of $4,511,000 for the nine months ended September 30, 2026, were 122% higher than the $2,036,000 incurred during the comparable period in 2025, due mostly to the acquisition of PSS and an increase in cost at EHP now that the health plan is operating.

 

During the nine months ended September 30, 2026 and 2025 the Company recorded no income tax benefit or provision.

 

For the nine months ended September 30, 2026, the Company reported a net loss of $4,312,000 compared to $2,026,000 for the same period a year earlier. The net loss was primarily due to the acquisition of PSS.

 

Liquidity and Capital Resources

 

The Company’s primary sources of liquidity are from equity transactions discussed below.

 

Net cash used in operating activities for the nine months ended September 30, 2026, was $4,035,000 as compared to $1,448,000 for the same period a year earlier. This change is primarily due to the Company’s acquisition of PSS and higher expenses of EHP now that the plan has begun operations. The Company used cash in investing activities for the nine months ended September 30, 2026 and 2025 of $13,000 and $981,000, respectively, due primarily to purchases of fixed assets and development costs.

 

The Company raised total proceeds from the issuance of common stock, warrants and notes payable of an aggregate of $1,030,000 and $2,365,000 during the nine months ended September 30, 2026 and 2025, respectively. As a result of these issuances, as of September 30, 2026, there were outstanding 28,682,988 shares of the Company’s Common Stock. In addition, the Company issued subordinated notes payable and attached common stock warrants to the Company’s CEO of an aggregate of $850,000 during the quarter ended September 30, 2026 compared to $0 during the same period in 2025.

 

 

For this sale of securities in connection with private placement, no general solicitation was used, no commissions were paid, all participants in the private placement were accredited investors, and the Company relied on the exemption from registration available under Section 4(a)(2) and/or Rule 506(b) of Regulation D promulgated under the Securities Act with respect to transactions by an issuer not involving any public offering.

 

The Company presently intends to use the net proceeds from the private placement principally to execute the plan of Elite Health to establish a managed care organization that will operate as a Medicare Advantage plan for seniors.

 

17

 

The Company presently intends to use the net proceeds from the private placement principally to execute the plan of Elite Health to establish a managed care organization that will operate as a Medicare Advantage plan for seniors.

 

In the nine months ended September 30, 2026, the Company incurred a net loss of $4,312,000 compared to $2,026,000 in the same period of fiscal year 2025. The Company has received state and Federal approval to operate as a Medicare Advantage plan and began operating as a Medicare Advantage plan on January 1, 2026. As a result, it recorded no revenue from its health plan in 2025 and has significant expenses. The Company has funded operations through the sale of common stock. The Company had an accumulated deficit in stockholders’ equity of $16,561,000 and $12,249,000 at September 30, 2026 and December 31, 2025, respectively; cash and cash equivalents of $740,000 and $3,758,000 at September 30, 2026 and December 31, 2025, respectively; and working capital of $136,000 and $3,144,000 at September 30, 2026 and December 31,2025, respectively. In addition, the Company currently does not have access to capital through a line of credit nor other readily available sources of capital. Together, these factors raised substantial doubt regarding the Company’s ability to continue as a going concern at September 30, 2026.

 

However, management has considered its plans to continue the Company as a going concern, concentrating on the establishment and operation of managed health care plans. The Company raised gross proceeds of approximately $14 million in support of this business opportunity through the sale of its Common Stock in a private placement and believes it has access to additional capital in 2026. However, the Company is operating in a highly competitive business environment with complex regulatory and operational challenges. In order to be successful, the Company must significantly increase its health care membership and hire additional key members of management, both of which will take significant capital and time. As a result, the Board of Directors authorized management to consider and pursue strategic alternatives involving the Company. The strategic review authorized by the Company’s Board of Directors will include consideration of potential equity or debt capital, selling certain assets, including one or more of its operating businesses, or other strategic financings or transactions, such as a merger or disposition of all of its assets. No timetable has been established to achieve any transaction and there can be no assurance that any strategic transaction, if implemented, will result or result in an increase in stockholder value. The Company may terminate its review at any time and may ultimately determine not to pursue a strategic transaction.

 

Management believes its plan alleviates the substantial doubt and that it will be successful in its planned business initiatives and will be able to continue as a going concern through at least the next twelve months. However, failure to consummate a strategic transaction, including a financing, merger, sale or disposition of all or substantially all of its assets, or other strategic alternative, could have a material adverse effect on the Company’s liquidity, financial condition and ability to continue operations. There can be no assurance that any such transaction will be completed on acceptable terms, or at all. 

 

Risk Factors

 

We desire to take advantage of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The factors listed under the caption “Risk Factors” in Annual Report on our Form 10-K for the fiscal year ended December 31, 2025, have affected or could affect our actual results and could cause such results to differ materially from those expressed in any forward-looking statements made by us. Investors should carefully consider these risks and speculative factors inherent in and affecting our business and an investment in our common stock.

 

18

 

Disclosure Regarding Forward Looking Statements

 

The Securities and Exchange Commission encourages companies to disclose forward looking information so that investors can better understand a company's future prospects and make informed investment decisions. This document contains such "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, particularly statements anticipating future growth in revenues and cash flow. Words such as "anticipates," "estimates," "expects," "projects," "targets," "intends," "plans," "believes," "will be," "will continue," "will likely result," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are based on management's present expectations about future events. As with any projection or forecast, they are inherently susceptible to uncertainty and changes in circumstances, and the Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of such changes, new information, future events or otherwise.

 

The Company operates in a highly competitive and rapidly changing environment and in businesses that are dependent on our ability to: achieve profitability; increase revenues; sustain our current level of operations; maintain satisfactory relations with business partners; attract and retain key personnel; maintain and expand our strategic alliances; and protect our intellectual property. The Company's actual results could differ materially from management's expectations because of changes in such factors. New risk factors can arise and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. Factors that could cause actual results to differ materially from those currently anticipated include the following:

 

 

●

Uncertainties relating to our ability to successfully implement our strategy of developing a Medicare Advantage plan under our Elite Health subsidiaries;

 

●

Uncertainty over our ability to achieve a Medicare Advantage license in California in a timely manner, acquire managed health consumers in California, expand consumer enrollment beyond this initial state, or diversify and expand our portfolio of products and services, our business and results of operations will be significantly impaired;

 

●

Our ability to raise capital in the future on satisfactory terms;

 

●

Our financial condition and liquidity;

 

●

Uncertainty over our ability to successfully implement management's plan to improve liquidity, including the ability to manage costs, systems and growth;

 

All forward looking statements should be considered in the context of the risks and other factors described above and in "Risk Factors" (Part I, Item 1A of the Company’s Annual Report on Form 10-K for the Fiscal Year ended December 31, 2025), "Quantitative and Qualitative Disclosures about Market Risk" (Part II, Item 7A of the Company’s Annual Report on Form 10-K for the Fiscal Year ended December 31, 2025), and "Management’s Discussion and Analysis" (Part I, Item 2 of this Form 10-Q).  We undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events, or otherwise.

 

Investors should also be aware that while the Company might, from time to time, communicate with securities analysts, it is against the Company's policy to disclose to them any material non-public information or other confidential commercial information. Accordingly, investors should not assume that the Company agrees with any statement or report issued by any analyst irrespective of the content of the statement or report. Furthermore, the Company has a policy against issuing or confirming financial forecasts or projections issued by others. Thus, to the extent that reports issued by securities analysts or others contain any projections, forecasts or opinions, such reports are not the responsibility of the Company.

 

19

 

In addition, the Company’s overall financial strategy, including growth in operations, maintaining financial ratios and strengthening the balance sheet, could be adversely affected by increased interest rates, construction delays or other transactions, economic slowdowns and changes in the Company’s plans, strategies and intentions.

 

 

Item 3.  Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

 

Item 4.  Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company's reports under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. We do realize that we are a very small company and as a small company with only the officers and directors participating in the day to day management, with the ability to override controls, each officer and director has multiple positions and responsibilities that would normally be distributed among several employees in larger organizations with adequate segregation of duties to ensure the appropriate checks and balances.

 

Our management evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based upon that evaluation, the Company’s Chief Executive Officer concluded that the Company’s disclosure controls and procedures were not effective as of the end of the period covered by this report for the information required to be disclosed by the Company in the reports it files or submits under the Securities Exchange Act of 1934, as amended, to be recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, due to the material weakness in internal control over financial reporting described below.

 

Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. The Company’s internal control over financial reporting includes those policies and procedures that:

 

(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company.

 

(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company.

 

20

 

(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

 

Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives.

 

Our management assessed the effectiveness of the Company’s internal control over financial reporting as of September 30, 2026. A material weakness is a control deficiency, or a combination of control deficiencies in internal controls over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. In connection with the assessment described above, management identified a material weakness as of September 30, 2026 pertaining to independent verification of changes to vendor information by a member of the accounting team, along with separate manager approval of such change and verification.

 

Changes in Internal Control over Financial Reporting

 

While there have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter ended September 30, 2024, management is in the process of developing plans to remediate the material weakness identified above.

 

21

 

PART II – OTHER INFORMATION

 

 

Item 1.  Legal Proceedings

 

The Company is subject to lawsuits, investigations and potential claims arising out of the ordinary conduct of its business. The Company is not currently involved in any material litigation. 

 

Item 2.  Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities Unregistered Sales of Equity Securities and Use of Proceeds

 

 

Item 3.  Defaults Upon Senior Securities

 

Not applicable.

 

Item 4.  Submission of Matters to a Vote of Security Holders

 

Not applicable.

 

 

Item 5.  Other Information

 

Not applicable.

 

 

22

 

Item 6.  Exhibits

 

10.1

Form of Senior Unsecured Promissory Note between the Registrant and Dr. Prasad Jeereddi filed as exhibit 10.1 to Form 8-K and incorporated herein by reference.

   

10.2

Form of Warrant Agreement between the Registrant and Dr. Prasad Jeereddi filed as exhibit 10.2 to Form 8-K and incorporated herein by reference.

   

31.1

Certification of President and Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

   

31.2

Certification of Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed herewith.

   

32.1

Certifications of Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial Officer) pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.

   

101

Interactive Data Files providing financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 in iXBRL (Inline eXtensible Business Reporting Language). Pursuant to Regulation 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, and are otherwise not subject to liability.

   

104

The Cover Page Interactive Data File, formatted in Inline XBRL (included within the Exhibit 101 attachments)

 

23

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Elite Health Systems, Inc.

 

(Registrant)

   
   

Date:  November 20, 2026

By  /s/ Dr. Prasad Jeereddi 

 

Prasad Jeereddi           

 

Director, President and CEO

   
  By  /s/ Kenneth Minor 
 

Kenneth Minor 

CFO and Secretary 

 

 

24

Keep reading